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Supplementary Figure 1: Group 1 families. Pedigree representation of the 49 Group 1 families, where a
variant has been detected either in an locus with high/moderate level of evidence for gene-disease
association, or in one that is emerging from basic research or mutated in other inherited hematological
syndromes with high risk of MDS/AML (FML001-FML049). Index case of each family is indicated with an arrow.
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Supplementary Figure 2: Group 2 families. Pedigree representation of the 37 Group 2 families, where the
causal genetic lesion has not been defined (FML050-FML086). Index case of each family is indicated with an
arrow. Asterisks indicate family members other than the index case where samples were also subjected to WES.
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Supplementary Figure 3: RUNX1 germline deletions. (a) Array CGH analysis of salivary DNA from II.2 of
family FML031 revealed a RUNX1 666kb deletion (chr21: 36389457- 37055677). (b) A RUNX1 compound
duplication (chr21: 36594603- 36768032) and deletion (chr21:36349450-36572837) was identified by Array
CGH in patient II.5 of family FML029. (c) SNP array in II.2 of family FML030 identified a RUNX1 deletion
(chr21: 36400658-36972948). (d) MLPA analysis of multiple individuals/samples from pedigrees FML029
(II.5, III.2, III.3 and III.4), FML030 (II.2 and I.1) and FML031 (tumour and salivary DNA from II.2, samples from
I.2 were not available) confirmed heterozygous loss of RUNX1 exons 1 and 2 (shown in green) in affected
individuals, with normal peak ratios in remaining exons. (Key: PB-peripheral blood; sDNA-salivary DNA; Tm-
tumour; CR- complete remission; post BMT- post allogeneic HSCT).
Supplementary Figure 4:
Supplementary Figure 4: Filtering pipeline. Schematic representation of the different steps followed to
prioritize the most relevant candidate genes in our series.
Supplementary Figure 5:
Supplementary Figure 5: Novel candidate loci meeting the selection criteria. Number of families with variants
in the 65 novel candidate loci meeting the selection criteria. (Novel variants: not present in control population
ExAC database; LoF variants: frameshift insertions/deletions/substitutions/duplications and nonsense variants;
Missense variants: missense and nonframeshift/inframe variants). Asterisks indicate genes mutated also in
sporadic AML based on The Cancer Genome Atlas AML database44 and Tyner et al. data45.
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Supplementary Figure 6: Sanger sequencing validation of selected genetic variants. Sanger sequencing traces
confirming the presence of 47 variants previously identified by WES (within 22 selected genes), in the
corresponding familial samples. Segregation was also validated in all the cases when material from more than
one affected individual in the same family was available.
Supplementary Figure 7
Supplementary Figure 7: DHX34 variants fail to promote the binding of UPF2 and UPF3 to UPF1. HEK293T
cells depleted of DHX34 with a specific siRNA or transfected with a scrambled non-targeting siRNA (-) were
co-transfected with FLAG-UPF1 and a siRNA-resistant wild-type (WT) T7-DHX34 or the indicated DHX34
variants (with empty vector plasmids as controls (-)). Following anti-FLAG immunoprecipitation, Input (0.5%)
and anti-FLAG IPs (20%) were analysed by Western blotting with antibodies for the indicated proteins.
Uncropped Western blots are provided as a Source Data file.
